Related Experiment Video

Updated: Jan 10, 2026

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
08:51

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

2.0K

Long-Term Thrombotic Events in Patients with Myocardial Infarction: Proteomic Analysis of Platelets and Plasma

A S Anisimova1, G I Rusakovich2, E V Maryukhnich1

  • 1Russian University of Medicine; Davydovsky Municipal Clinical Hospital.

Kardiologiia
|November 26, 2025
PubMed

Insights

Researchers identified specific platelet proteins linked to a higher risk of thrombotic complications in acute myocardial infarction (AMI) patients undergoing dual antiplatelet therapy (DAPT). These findings may help predict and prevent future cardiovascular events.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Proteomics

Background:

  • Dual antiplatelet therapy (DAPT) is crucial for managing acute myocardial infarction (AMI).
  • Identifying patients at high risk for thrombotic complications during DAPT is essential for personalized treatment strategies.

Purpose of the Study:

  • To determine factors associated with an increased risk of thrombotic complications in AMI patients on DAPT.
  • To investigate the role of hemostasis parameters and proteomic profiles in predicting these complications.

Main Methods:

  • A prospective clinical study involving 98 AMI patients.
  • Assessment of hemostasis parameters and quantification of plasma and platelet proteome before and after DAPT.
  • 12-month follow-up for thrombotic complications and statistical analysis.

Main Results:

  • Statistically significant differences in protein concentrations were observed between patients with and without thrombotic complications.
  • Platelet proteins including von Willebrand factor, complement component C8 β-chain, and cation-independent mannose-6 phosphate receptor were associated with increased long-term thrombotic risk.

Conclusions:

  • Specific protein concentrations in AMI patients on DAPT are linked to an elevated risk of thrombotic complications.
  • Further validation through randomized prospective studies is recommended before clinical implementation.

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

983
Microfluidics in Assessing Platelet Function06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.5K

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
769
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
268
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.6K